Vriesendorp H M, Chu H, Ochran T G, Besa P C, Champlin R E
University of Texas M.D. Anderson Center, Houston 77030.
Bone Marrow Transplant. 1994;14 Suppl 4:S4-8.
The first bone marrow transplants (BMTs) in human patients were performed after conditioning with total body irradiation (TBI). TBI remains an important part of BMT protocols. The morbidity and mortality of BMT remains significant, but can be decreased by the introduction of optimized TBI regimens. This requires dosimetric control and a detailed analysis and description of the physics of the TBI procedure in every BMT center that utilizes TBI. Recommendations for such procedures are given. Radiobiological models are of help in developing less toxic TBI procedures, but can only be effective after dosimetric control has been obtained and if the influence of other variables on the outcome of BMT are taken into account. Fractionated TBI (fraction size over 3.0 Gy or higher) appears to be more effective and better tolerated than single fraction TBI. Lung shielding is possible during TBI. Smaller organs or organs that cannot be imaged easily are not recommended for shielding. Radiolabeled immunoglobulins are but low molecular weight bone seeking radioisotopes and are not expected to improve the therapeutic ratio of TBI. Other variables in BMT are more difficult to quantify and model than TBI (e.g. high-dose chemotherapy, graft-versus-host disease) and will be more difficult to optimize.
人类患者的首例骨髓移植(BMT)是在进行全身照射(TBI)预处理后实施的。TBI仍是BMT方案的重要组成部分。BMT的发病率和死亡率仍然很高,但通过引入优化的TBI方案可以降低。这需要剂量控制以及对每个使用TBI的BMT中心的TBI程序物理过程进行详细分析和描述。文中给出了此类程序的建议。放射生物学模型有助于开发毒性较小的TBI程序,但只有在获得剂量控制并且考虑到其他变量对BMT结果的影响后才会有效。分次TBI(分次剂量超过3.0 Gy或更高)似乎比单次TBI更有效且耐受性更好。在TBI期间可以进行肺部屏蔽。不建议对较小的器官或不易成像的器官进行屏蔽。放射性标记的免疫球蛋白只是低分子量的亲骨性放射性同位素,预计不会提高TBI的治疗比。BMT中的其他变量比TBI更难量化和建模(例如高剂量化疗、移植物抗宿主病),并且更难优化。